Following protracted negotiations, Fieldfisher has successfully advised Mr. Ivan Berkes on his exit from Dr. Max Pharma Limited and the Dr. Max Private Label project of the Penta investment group for a confidential sum. Dr. Max Pharma Limited has more than 800 pharmacies in its portfolio and annual revenues of about €650m.
Over the last few years, under Mr. Berkes’s management, Dr. Max Pharma has been created and developed to deliver a portfolio of over 350 Own and Exclusive Private label products across a full range of pharmacy sales segments inclusive of Food Supplements, OTC and Rx Medicines, Medical Devices, Cosmetics and Special Foods. Dr. Max Pharma has grown to be a tangible contributor to overall Penta group performance whilst also bringing a wider choice and value to customers of Dr. Max pharmacies across Poland, Czech Republic and Slovakia.
As of Sept 18 2015, the Penta Group, a central European investment group with a portfolio of investments in real estate, aerospace, banking, hospitals and healthcare, manufacturing, technology, betting and other industries, will become the sole shareholder of Dr. Max Pharma Limited. Mr Berkes also formally steps down as Director of Dr. Max Pharma Limited on the same date. During the upcoming 6 month transition period, Mr. Berkes will be working with the Dr. Max Group as a Board Advisor to ensure the smooth transfer of his knowledge and duties following which he plans to pursue further development and investment opportunities in the health sector in other territories such as Germany, UK and China.
The Fieldfisher team included corporate advisory and structuring from Christine Phillips and Colin Gibson. The transaction also involved strategic advice on tax structuring from Andrew Prowse.
Sign up to our email digest